HOME >> BIOLOGY >> NEWS
Closing in on treatment for Charcot-Marie-Tooth disease?

Charcot-Marie-Tooth (CMT) is a hereditary disorder of the peripheral nervous system that strikes 1 person in every 2500. Increasing debilitation of the muscles ultimately leads to their disappearance in the lower legs, feet and hands. Now, researchers from VIB (the Flanders Interuniversity Institute for Biotechnology) have discovered a piece of the molecular puzzle of this disease. Two small 'heat shock' proteins turn out to be crucial - faults in the coding genes lead to the disease. Additional research has shown that these proteins play an important role in many other neurodegenerative disorders as well. This research moves us a step closer to the development of new therapies.

CMT, a serious disorder without a cure

CMT, the most common hereditary disorder of the peripheral nervous system, leads to debilitation of the muscles in the lower legs, feet and hands. The clinical picture is extremely variable, but older patients sometimes require a wheelchair. Today, only supportive treatment is available; there are still no effective therapies to retard or stop the progress of the disease. More insight into the molecular processes of this disease is essential for diagnosis and potential treatment. And exploration of the genes involved is a crucial step in this.

VIB research findings

Joy Irobi and her colleagues - under the direction of Vincent Timmerman and Peter De Jonghe of the Department of Molecular Genetics, University of Antwerp - are concentrating on the genetic and biological study of hereditary disorders of the peripheral nervous system. The largest cells in our body, our peripheral neurons can be 1 meter long in bundles of nerve fibers extending from the spinal cord to the feet.

Recently, the researchers in Antwerp have found mutations in the genetic code of two small 'heat shock' proteins (HSPs) in a number of people with CMT. In stress situations, cells produce HSPs that act as 'chaperones', stabilizing
'"/>

Contact: Ann Van Gysel
ann.vangysel@vib.be
32-9-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
7-May-2004


Page: 1 2

Related biology news :

1. Closing in on the cellular culprits of schizophrenia
2. Researchers Closing In On Gene For Paralytic Disorder
3. Leader in cancer treatment and prevention research honored
4. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
5. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
6. New treatment for fibromyalgia
7. The impact of genetic variations on the treatment of early rheumatoid arthritis
8. OneWorld Health compiles comprehensive state of infectious diarrhea treatments, potential solutions
9. Early clinical treatment can halt progression of Alzheimers disease, UCI researchers find
10. Colleagues to recognize research leadership in cancer detection, prevention and treatment
11. New view of leukemia cells identifies best treatment options, Stanford researchers say

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Closing treatment for Charcot Marie Tooth disease

(Date:7/27/2014)... Microorganisms like bacteria and fungi can evade treatment by ... antifungal drugs. These permanent mutations were once thought to ... Now a new study has shown that microorganisms can ... as epimutations -- to gain the benefits of drug ... was discovered in a fungus called Mucor circinelloides, it ...
(Date:7/27/2014)... Cancer Institute have found that targeting a molecule in ... according to research published in Nature today ... Queen Mary University of London, have found that a ... to repair itself after chemotherapy or radiotherapy, which kill ... FAK from blood vessels that grew in melanoma or ...
(Date:7/27/2014)... data from over 18,000 patients, scientists have identified ... in Parkinson,s disease, including six that had not ... Nature Genetics , was partially funded by the ... scientists working in NIH laboratories. , "Unraveling the ... the multiple mechanisms involved in this complex disease, ...
Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New drug target can break down cancer's barrier against treatment 2NIH scientists find 6 new genetic risk factors for Parkinson's 2
(Date:7/25/2014)... (PRWEB) July 25, 2014 According to ... "Biological Drugs Market - Global Industry Analysis, Size, Share, ... biological drugs market is estimated at USD 161,056.5 million ... CAGR of 10.1% from 2014 to 2020, to reach ... , The biological drugs market is witnessing a significant ...
(Date:7/25/2014)... , July 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, today announced financial results for the period ... Financial Summary: , Reported cash and cash equivalents ... $137,000 at December 31, 2013.  , Reported a ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... Calif. , July 24, 2014  Asterias ... in the emerging field of regenerative medicine, announced ... of a presentation to investors on Tuesday, July ... PDT.  The presentation will include an overview of ... access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at ...
Breaking Biology Technology:Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
Cached News: